--- title: 'Clinical Daily Summary: What Happened on October 8, 2026' headline: Argenx ends Phase 3 Sjögren’s trial after futility review description: The day also brought new data on inherited cancer testing, a first-in-human trial clearance and Taiwan approvals for a lung-cancer study. url: https://thebench.bio/news/clinical/2026-10-08 topic: clinical date: '2026-10-08' covers: - '2026-10-08' date_published: '2026-10-08T12:02:35Z' date_modified: '2026-10-08T12:02:35Z' sources: 5 publisher: The Bench (thebench.bio) --- # Clinical Daily Summary: What Happened on October 8, 2026 **Argenx ends Phase 3 Sjögren’s trial after futility review** The day also brought new data on inherited cancer testing, a first-in-human trial clearance and Taiwan approvals for a lung-cancer study. ## Today in brief Argenx ended its Phase 3 UNITY study of efgartigimod in Sjögren’s disease after a review concluded it was unlikely to meet its primary endpoint. [1] [2] The company reported no new safety signals. Its shares fell about 18% in Brussels trading. [1] [2] ## Argenx halts its Sjögren’s trial after interim analysis An independent monitoring committee recommended ending UNITY for futility, meaning the trial was unlikely to show the required benefit. [1] [2] Argenx had expected results in the second half of 2027. [1] Argenx plans to review the full dataset after the trial closes and the database is locked. [1] [2] Sjögren’s is an autoimmune disease with no approved disease-modifying treatments, though some biologics are used off-label. [2] Argenx said its Phase 2 study of FB102 met its primary endpoint in celiac disease and that it plans to advance the drug into Phase 3. [1] The company plans to present the data at a future medical meeting and continue testing FB102 in vitiligo and alopecia areata. [1] ## Also worth knowing - Memorial Sloan Kettering researchers analyzed nearly 40,000 adults across 32 solid tumor types and estimated that age cutoffs could exclude 72% of people carrying pathogenic inherited variants. Finding these variants can inform treatment, cancer surveillance and testing of relatives. [3] - The FDA cleared Dignify Therapeutics’ investigational new drug application for DTI-117, an on-demand treatment candidate for neurogenic bowel dysfunction. The company plans to dose its first healthy volunteer in November. [4] - Lantern Pharma received regulatory and ethics clearances in Taiwan to start the next part of its Phase 2 HARMONIC study, testing LP-300 with chemotherapy in lung cancer. The revised protocol allows up to eight treatment cycles, up from six. [5] ## The day in numbers - **72%**: Estimated share of inherited cancer-variant carriers who could be missed by age-based testing criteria. [3] - **18%**: Approximate fall in Argenx shares after the UNITY trial was stopped. [1] ## Also published - [ACT Brief: AI and Protocol Design, Site Training Readiness, and GLP-1 Unmet Needs](), Applied Clinical Trials - [ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care](), Pharmaceutical Executive - [Podcast: Customising clinical trials without increasing patient burden](), Clinical Trials Arena ## Sources 1. [Argenx halts Phase 3 Sjögren’s trial, sending shares tumbling](), European Biotechnology, 2026-10-08 2. [Argenx cans Phase III Vyvgart Sjögren’s study on predicted efficacy fail ](), Clinical Trials Arena, 2026-10-08 3. [Age-Based Genetic Testing Misses 72% of Patients with Inherited Cancer Variants](), Inside Precision Medicine, 2026-10-08 4. [Dignify Therapeutics secures FDA clearance for Phase I DTI-117 trial](), Clinical Trials Arena, 2026-10-08 5. [Lantern Pharma secures Taiwan clearances for Phase II NSCLC study](), Clinical Trials Arena, 2026-10-08 --- The Bench wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: